Open AccessPoor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients
Author(s) -
Karthik Venkatachalam,
Andrew F. Malone,
Brittany Heady,
Rowena Delos Santos,
Tarek Alhamad
Publication year - 2020
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002914
Subject(s) - medicine , oncology , ipilimumab , cancer , immunosuppression , kidney cancer , melanoma , nivolumab , immunotherapy , cancer research
Checkpoint inhibitors are now frequently used for oncologic conditions. The impact of these therapies in solid organ transplant recipients was not assessed in clinical trials. Subsequent case reports highlight the major detrimental interactions of checkpoint inhibitors and the high risk of allograft rejection with their use. Patient outcomes have not been assessed in long-term follow-up.